Drug intelligence / Profile preview

mycophenolate mofetil + azathioprine

Development stage: Unknown
Lead developer: Roche
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

Mycophenolate mofetil and azathioprine are immunosuppressive drugs that inhibit purine synthesis through different mechanisms. Mycophenolate mofetil is a prodrug of mycophenolic acid that inhibits inosine monophosphate dehydrogenase, depleting guanosine nucleotides in lymphocytes. Azathioprine converts to 6-mercaptopurine and inhibits purine nucleotide synthesis. This combination is used in treating various autoimmune conditions, interstitial lung disease, and preventing organ rejection after transplantation.

Targets

PPAT (Amidophosphoribosyltransferase)IMPDH (Inosine-5'-monophosphate dehydrogenase 1)

Beyond the preview

Go deeper on mycophenolate mofetil + azathioprine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mycophenolate mofetil + azathioprine.

Explore the full profile